Investor Calendar Invites You to the TG Therapeutics, Inc. Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Monday, March 7, 2016

NEW YORK, NY / ACCESSWIRE / March 7, 2016 / TG Therapeutics, Inc. (NASDAQ: TGTX) will host a live conference call and webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held today, Monday, March 7, 2016 at 4:30 PM Eastern Time.

To participate in this event, dial 877-407-8029 domestically, or 201-689-8029 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174780 as well as via the TG Therapeutics website (www.tgtherapeutics.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.tgtherapeutics.com.

About TG Therapeutics, Inc.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

SOURCE: Investor Calendar

ReleaseID: 437510